Company intelligence / Profile preview
Sapu Nano
Sydney, New South Wales, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Sapu Nano's lead product Sapu003, utilizing proprietary Deciparticle™ nanotechnology to deliver everolimus intravenously, is in a Phase 1 trial open to adults with advanced breast cancer in Australia; preclinical results indicate full bioavailability and potentially enhanced clinical benefit versus oral therapy, but human efficacy results are not yet available
- Therapeutic areas
- Oncology
- Modalities
- NanoparticleSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
SOCRU (Phase 1 clinical unit, Australia)Ingenū (clinical research organization)Medicilon (preclinical development partner)
Beyond the preview
Go deeper on Sapu Nano.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sapu Nano.